Background-Serum bilirubin is an endogenous antioxidant that is routinely measured before a statin is prescribed primarily to assess liver function, but the association with cardiovascular disease (CVD) in this population has not been explored. Method and Results-We identified patients from a United Kingdom primary care database (The Health Improvement Network) with measurements of serum total bilirubin levels recorded 3 months before the first statin treatment between January 1, 2000, and December 31, 2010, and no history of liver disease or CVD. In total, 130 052 patients met the inclusion criteria, and after a median follow-up of 43 months, there were 7850 CVD events. In men, the incidence of CVD in the lowest decile category of bilirubin (1-6 mol/L [0.06 -0.35 mg/dL]) was 215 per 10 000 person-years compared with 163 per 10 000 person-years in the highest decile (19 -40 mol/L [1.1-2.3 mg/dL]). Similar differences were seen for women. After conventional CVD risk factors were accounted for, the associations with bilirubin were nonlinear (L shaped), and the models predicted that, compared with patients with a bilirubin level of 10 mol/L (0.6 mg/dL), those with a similar CVD risk profile but a bilirubin level of 5 mol/L (0.3 mg/dL) had an 18% (95% confidence interval, 9 -27) higher risk of any CVD event, a 34% (95% confidence interval, 13-56) higher risk of myocardial infarction, and a 33% (95% confidence interval, 21-46) higher risk of death resulting from any cause. Conclusions-Serum bilirubin level measured before a statin prescription to assess liver function is an independent risk factor for CVD and death in both men and women. (Circulation. 2012;126:2556-2564.)
bilirubin seems to be particularly effective at suppressing the oxidation of blood lipids, including low-density lipoprotein (LDL). 6, 8, 11 In addition, direct application of bilirubin to vascular endothelial tissue appears to improve markers of oxidative stress and cellular dysfunction. 12, 13 These observations suggest a role in protecting against cardiovascular disease (CVD); indeed, a number of small prospective studies have reported much lower rates of CVD for men with comparatively higher bilirubin levels after accounting for other risk factors. 14 Less is known about the association in women. Furthermore, cohort studies have shown that homozygosity for the UGT1A1*28 allele is associated with a much lower risk of CVD events. 15, 16 UGT1A1*28 is not associated with conventional CVD risk factors 12, 13 but has been linked to a significantly smaller brachial artery diameter and increased cold pressor test reactivity in young people, suggesting a beneficial influence on the size and structure of arteries. 3 Thus, serum bilirubin level may be an independent marker for environmental and genetically determined CVD risk. However, the small sample sizes of previous studies mean that it is difficult to understand the clinical implications for women and the wider population.
The aim of our study was to assess prospectively whether serum bilirubin level measured routinely before the prescription of a statin, primarily to assess liver function, was also related to future CVD events and death resulting from any cause in a large primary care patient population.
Method Data Source
The Health Improvement Network (THIN) primary care database includes anonymized records entered with VISION software on Ͼ10 million patients from the United Kingdom (http://csdmruk.cegedim. com). All diagnoses, interventions, symptoms, and referrals to secondary care are electronically recorded as Read codes, which is a hierarchical coding system used in UK primary care. 17 Clinical measurements and laboratory tests are also included, as well as data on all drug prescriptions. Postcode-level variables are available, including the Townsend index, which is a composite measure of social deprivation derived from figures on unemployment, car ownership, home ownership, and household overcrowding in the local area. A date is provided that relates to the year in which the general practice achieved a standardized mortality rate similar to the general population and is called the acceptable mortality recording date. 18 This can be used to restrict analyses to time periods after which primary care clinicians were using their computer systems adequately. The demographics and consultation behavior in the THIN data are broadly representative of the general practice population, 19 and clinical diagnoses recorded by general practitioners (primary care clinicians) have recently been shown to be comparable to other reliable sources. 20 The THIN scheme of providing anonymized data to researchers was approved by the National Health Service South-East Multi-Center Research Ethics Committee in 2002, and the University College London Scientific Review Committee approved the present study.
Study Population
All patients with a total bilirubin level, alkaline phosphatase as a measure of biliary function, and at least 1 transaminase (alanine aminotransferase or aspartate aminotransferase) as a measure of liver function recorded in the 3 months before their first statin prescription between January 1, 2000, and December 31, 2010, were included in the study. This population was selected because patients prescribed statins have important CVD risk factors recorded before prescription and have a broadly similar risk profile (ie, at least a 20% 10-year risk of CVD). There is evidence that bilirubin levels may increase in response to disease processes, possibly as a result of stimulation of heme oxygenase 21 ; therefore, to reduce the risk of any dilution effect, patients with a history of CVD at the time of first prescription were excluded. Likewise, patients with a history of diseases that can affect bilirubin levels, including liver disease, alcoholism, and hemolytic anemia, were excluded. Patients were followed up from first statin prescription to the event of interest, death, the date they left the practice, or the end of the study period.
Exposure
Serum total bilirubin level in standard international units of micromole per liter (divide by 17.1 to convert to milligrams per deciliter) measured before statin prescription was the exposure variable. Bilirubin levels have been shown to be fairly stable within healthy individuals, with only Ϸ5% variation between tests on the same person on 2 different days. 4 The upper limit of normal for bilirubin levels is often 17 or 21 mol/L. However, applying this cutoff would have excluded a large numbers of healthy individuals with the Gilbert genotype, which is part of the normal genetically determined variation in bilirubin level. 2, 15 Therefore we considered normal bilirubin levels to range between 1 and 40 mol/L, with the upper level approximating 3 SD from the mean levels reported for healthy people with the Gilbert genotype. 2, 15 
Outcomes
The main outcome was CVD event (diagnosis or cause of death), including myocardial infarction (MI), ischemic heart disease, angina, cerebrovascular accident, or surgical procedures related to these events. Lists of Read codes for identifying CVD events were developed with the use of previously reported guidelines. 22 Within CVD, we examined coronary heart disease (CHD), including MI, ischemic heart disease, or angina. We also examined MI and death resulting from any cause as outcomes that are probably less susceptible to any misclassification bias. Death resulting from any cause was determined by the presence of a date of death in the patient records.
Explanatory Variables
Conventional CVD risk factors typically recorded before statin prescription were selected as potential confounders in the primary analyses. These included age at first prescription, sex, self-reported smoking (current smoker, ex-smoker, never smoker) and drinking status (current drinker, ex-drinker, never drinker), body mass index, blood pressure (systolic and diastolic), high-density lipoprotein, LDL, ethnicity, and the Townsend index of social deprivation. When multiple measurements were recorded, the one closest to the date of the first statin prescription was used. Smoking status and drinking status are self-reported by patients and electronically recorded by primary care clinicians or practice nurses using structured data areas in the VISION system with options for "never," "ex," or "current." Smoking levels recorded in THIN have been shown to be very similar to those in other UK data sources. 23 Patients reporting to be never smokers or drinkers at the time of first statin prescription but were recorded as current or former smokers or drinkers previously were reclassified as ex-drinkers or ex-smokers. According to the 2001 Census, Ͼ92% of the United Kingdom population are of white European descent, and ethnicity is generally poorly recorded in UK primary care. To maintain statistical power, ethnicity was assumed to be European if not recorded.
Bilirubin purportedly has systematic antioxidant/antiinflammatory properties and may therefore protect against a range of diseases. Thus, certain patient characteristics could play a role in the causal pathway such as a history of diabetes mellitus, certain drug prescriptions, and a family history of CVD. These were included in a supportive analysis in combination with the risk factors in the primary analysis. Evidence of moderately raised alkaline phosphatase (Ͼ128 IU/L in men and Ͼ98 IU/L in women), alanine aminotransferase (Ͼ50 IU/L in men and Ͼ38 IU/L in women), or aspartate aminotransferase (Ͼ40 IU/L in men and Ͼ34 IU/L in women) was also included in this supportive analysis to account for any subclinical/undiagnosed hepatobiliary disease. We also accounted for antihypertensive or corticosteroid prescriptions in the 6 months before the first statin prescription, which have been associated with higher and lower bilirubin levels, respectively.
Statistical Analyses
Descriptive statistics included meanϮSD for continuous variables and percentages for categorical variables. Multivariable Poisson regression was used to estimate the incidence rate ratios of CVD, CHD, MI, and death after the addition of conventional cardiovascular risk factors (age, sex, blood pressure, LDL, high-density lipoprotein, body mass index, ethnicity, alcohol, smoking, social deprivation) and year of statin prescription. Continuous covariates were entered as such into any models. Restricted cubic spline interpolation was used to investigate nonlinear relationships between bilirubin levels and clinical events. This method can flexibly capture doseresponse relationships without the loss of information and potential biases associated with categorization. 11 Bilirubin level was transformed into restricted cubic splines with 4 knots (points at which the relationship with events is allowed to vary). The 4 knots were selected using the 5%, 35%, 65%, and 95% percentiles (percentiles recommended by Harrell 11 ), which correspond to 5, 9, 12, and 20 mol/L, respectively. The Akaike information criterion was used to identify the model explaining the most variation using the least degrees of freedom. 24 The cubic spline model was selected over the linear model (with log-transformed bilirubin) if the Akaike information criterion was improved by 4. The regression coefficients from restricted cubic spline models are difficult to interpret and so to visualize the results adjusted incidence rate ratios for each 1-mol/L increase in bilirubin were estimated assuming average values for all other risk factors. General practices were included as random effects in all models to account for overdispersion. All P values were 2 tailed, and a value of PϽ0.05 was considered statistically significant. All analyses were done with Stata version 12.
Supportive Analyses
It is possible that pretreatment serum bilirubin levels are also a marker for UGT1A-mediated statin metabolism 25, 26 and that any observed association in this statin-treated population could also reflect differential drug efficacy or toxicity. As a supportive analysis, we restricted the cohort to a subgroup with LDL recorded both before and within 1 year of statin prescription and adjusted the associations for LDL reduction. We also examined the relationship between pretreatment bilirubin levels and the incidence of any statin intolerance and, more specifically, statin-induced myopathy in the 6 months after the first prescription. Myopathy was defined by the use of Read codes for myopathy or muscle weakness combined with an entry of statin-related drug intolerance within the structured data area of the VISION system for recording adverse events.
Results
The cohort consisted of 69 209 men and 60 843 women. At the end of the study period (December 31, 2010), 16% of the cohort had transferred to a different general practice or were registered with practices that left the THIN scheme before the (11) 83 (10) 83 (10) 83 (10) 84 (11) 84 (10) 84 (10) 84 (11) SBP, mm Hg 141 (18) 142 (18) 142 (17) 142 (17) 142 (18) 143 (18) 142 (17) 142 (18) 143 (18) Current smoker 2565 (39) 1567 (33) 1637 (28) 1722 (27) 1614 (24) 1328 (21) 1995 (18) 1257 (16) 988 (14) Current drinker 4976 (75) 3596 (77) 4519 (77) 5088 (78) 5240 (79) 5048 (80) 8688 (80) 6226 (81) 5594 (82) Least deprived quintile 1591 (24) 1117 (24) 1558 (26) 1809 (28) 1829 (28) 1788 (28) 3342 (31) 2401 (31) 2248 (33) Non-European 239 (3) 183 (4) 204 (3) 184 (3) 176 (3) 177 (3) 256 (2) 174 (2) 171 (2) HDL indicates high-density lipoprotein; LDL, low-density lipoprotein; BMI, body mass index; DBP, diastolic blood pressure; and SBP, systolic blood pressure. *Categorical variables are reported as number (%) and continuous are reported as mean (SD). CVD indicates cardiovascular disease; IR, incidence rate; CI, confidence interval; CHD, coronary heart disease; and MI, myocardial infarction.
study period ended. The average age of cohort entry was 60 years for men and 64 years for women (Table 1) . Median serum total bilirubin levels were 11 mol/L (quartiles 1-3, 8 -15 mol/L) in men and 9 mol/L (quartiles 1-3, 7-12 mol/L) in women. Except for age and blood pressure, factors associated with a higher risk of CVD were associated with moderately lower bilirubin levels (Table 1) . Median cohort follow-up was 43 months (quartiles 1-3, 24 -64 months), during which there were 7850 CVD events. The incidence rates for CVD, CHD, MI, and death tended to decrease with increasing bilirubin decile categories for both sexes (Table 2) . After conventional risk factors were accounted for, the relationships with bilirubin were nonlinear with the 4-knot restricted cubic spline models a better fit to the data than linear models for all the events examined. The introduction of further knots to the data did not improve model fit. Bilirubin level was significantly related to all outcomes examined (PϽ0.0001). The models estimated an L-shaped relationship with steep negative associations up to Ϸ10 to 15 mol/L (the Figure) . Data used to generate these graphs are also reported for the median bilirubin level within decile categories (Table 3) . Using the median level of 10 mol/L as the reference value, the models predicted that patients with a similar CVD risk profile but a bilirubin level of 5 mol/L had an 18% (95% confidence interval [CI], 9 -27) higher risk of any CVD event, a 15% (95% CI, 5-26) higher risk of CHD, a 34% (95% CI, 13-56) higher risk of MI, and a 33% (95% CI, 21-46) higher risk of death (Table 3) . 81 (10) 81 (11) 81 (10) 81 (10) 82 (10) 82 (10) 82 (10) 82 (10) 82 (10) 82 (10) 82 (10) 140 (19) 141 (19) 141 (19) 141 (19) 142 (19) 143 (19) 142 (19) 143 (19) 143 (19) 143 (19) 142 (19) 863 (32) 1279 (29) 1499 (25) 1588 (22) 1516 (20) 1265 (18) 1022 (17) 752 (16) 1182 (14) 808 (12) 11774 (19) 1620 (60) (66) 408 (15) 646 (15) 820 (14) 878 (12) 906 (12) 799 (12) 645 (11) 483 (10) 766 (9) 613 (9) 6964 (11) 113 (4) 148 (3) 202 (3) 221 (3) 216 (3) 195 (3) 146 (2) 118 (2) 214 (2) 157 (2) 1730 (3) There were no significant interactions between bilirubin and sex. However, bilirubin distributions are different for men and women, and a stratified analysis was undertaken for CVD events with 4-knot cubic spline models fitted within sex. Bilirubin was significantly associated with CVD in men (PϽ0.0001) and women (PϽ0.0001), and the relationship was broadly similar with a level Ͻ10 mol/L associated with excess risk. The addition of covariates potentially on the causal pathway did not materially alter the associations. In the subgroup of patients with LDL recorded both before and within 1 year of statin prescription, there was a weak positive association with baseline bilirubin and LDL reduction with each 1-mol/L increase in serum bilirubin associated with a 0.002-mg/dL-greater average decrease in LDL (PϽ0.0001).
The relationship with CVD events and death in this subgroup was similar to that of the whole cohort, and the addition of LDL reduction to the model made no material difference in the associations. There was no significant association between pretreatment bilirubin level and recorded adverse events caused by statins in the 6 months after prescription.
Discussion
This is the first study to show that serum bilirubin level measured in the context of assessing liver function before statin prescription may provide information on disease risk in addition to conventional CVD risk factors. We found that, in people with a median serum bilirubin level of 10 mol/L compared with those with level of 5 mol/L and similar cardiovascular risk factors, there was an 18% (95% CI, 9 -27) higher risk of having a CVD event, a 15% (95% CI, 5-26) higher risk of CHD event, a 34% (95% CI, 13-56) higher risk of MI, and a 33% (95% CI, 21%-46) higher risk of death resulting from any cause. The results are directly applicable to primary care, and clinicians should be particularly concerned about the 1 in 5 patients at risk of CVD with bilirubin levels Ͻ6 mol/L. Smaller studies on bilirubin and CVD events have reported magnitudes of association similar to those seen in the present study. A meta-analysis of 11 studies conducted in men and published up to 2001 reported a 6.5% decrease in atherosclerotic disease rates per 1-mol/L increase in bilirubin level. 14 The Framingham Offspring Cohort Study (nϭ1780) reported a statistically significant 10% reduction in CVD events per 1.7-mol/L (0.1-mg/dL) increase in bilirubin, a 13% reduction in CHD, and a 13% reduction in MI over a 24-year follow-up after adjustment for conventional risk factors. 15 These findings are similar in magnitude to our results of an Ϸ3% to 5% decrease per 1-mol/L increase at bilirubin levels Ͻ10 to 15mol/L. The slightly weaker associations in THIN data may be due to adjustments for additional risk factors such as social deprivation or possibly the presence of some reverse causation in which bilirubin was measured closer to the event date than in other cohorts, and any stimulation of heme oxygenase in response to advancing yet undiagnosed disease may dilute the observed associations. 21 Prospective studies of individuals homozygous for UGT1A1*28, combined with cell and animal studies demonstrating cytoprotective properties, provide persuasive support for a causal relationship between bilirubin and CVD risk. 15, 16, 27 The Framingham Offspring Cohort Study (average age, 36 years at baseline) demonstrated that the 11% of participants homozygous for the UGT1A1*28 allele (mean bilirubin level, 19 mol/L) had 64% lower rates of CVD (95% CI, 26 -82; Pϭ0.005) and 70% lower rates of CHD (95% CI, 26 -88; Pϭ0.009) over a 24-year follow-up period. 15 Similar associations were reported for the cohort of East-Asian hemodialysis patients (nϭ661) in whom homozygosity for UGT1A1*28 was associated with 88% lower rates of CVD events (95% CI, 57-96; Pϭ0.001) and 75% lower rates of all-cause mortality (95% CI, 21-98; Pϭ0.019) over a 12-year period. 16 This study was also able to demonstrate that UGT1A1*28 heterozygotes had a 36% lower rate of CVD (95% CI, 11-55; Pϭ0.008) compared with patients with no copies of UGT1A1*28 even though heterozygotes tend to have bilirubin levels only 10% to 30% (1-3 mol/L) higher on average. Conversely, 2 large cohort studies in Danish populations found no association between a variant in linkage disequilibrium with the main UGT1A1 locus associated with bilirubin levels and the risk of ischemic heart disease. 28 Retrospective case-control studies have produced conflicting results. 28 One of the largest such studies reported odds ratios similar to the risk ratios of the prospective studies and identified some significant associations with other genes associated with bilirubin levels. 29 All other case-control studies did not report significant associations with UGT1A1 variation. 28 Bias is an issue for genetic association studies of conditions with high lethality like CVD, 30, 31 and associations would be biased toward the null hypothesis if the UGT1A1*28 allele improves the probability of surviving an acute CVD event or is associated with greater drug efficacy. Indeed, a recent clinical study reported a 60% increase in serum bilirubin levels during MI with levels remaining high for Ϸ21 hours. 32 This increase was strongly correlated with the level of serum heme oxygenase, and patients whose bilirubin level increased more dramatically during MI had CVD indicates cardiovascular disease; CHD, coronary heart disease; and MI, myocardial infarction. Four-knot spline transformation of bilirubin levels at percentiles corresponding to 5, 9, 12, and 20 mol/L. Multivariable Poisson models were used with the median bilirubin level of 10 mol/L used as the reference level; incidence rate ratios are estimated for median values within the bilirubin decile category. Model 1 was adjusted for age and sex; model 2 was adjusted for age, sex, ethnicity, body mass index, blood pressure, smoking status, drinking status, high-and low-density lipoprotein, social deprivation, and year of statin prescription. Bilirubin level was significantly associated with all events in model 2 (PϽ0.0001).
significantly better collateral flow into the ischemic myocardium. 32 Although this was a small study, it raises the possibility of survival bias in case-control studies of alleles influencing bilirubin levels and CVD. Further replication in large cohorts with a young recruitment age, extended followup, careful recording of CVD-related drug prescriptions, and inclusion of variants influencing bilirubin levels in addition to UGT1A1*28 2, 33 is required to clarify the relationship between alleles causing hyperbilirubinemia and CVD risk.
Randomized, controlled trials to examine the effect of agents causing moderate increases in serum bilirubin on the risk of CVD also could help us understand whether a causal relationship exists. Niacin (vitamin B 3 ), for instance, can increase bilirubin levels by stimulating heme oxygenase activity and is sometimes used as a provocation test for the Gilbert syndrome; a 50-mg intravenous injection is associated with a 23-mol/L average increase in people with the Gilbert syndrome and a 10-mol/L average increase in patients without the condition. 34 A meta-analysis of randomized, controlled trials reported that 1 to 3 g/d niacin can reduce CVD events by Ϸ25%. 35 Part of the mechanism appears to be increases in high-density lipoprotein, although an increase in bilirubin was recently shown to explain some of the beneficial effects at least in animal models and human vascular endothelial tissue. 36 It would be interesting to explore whether baseline bilirubin levels and UGT1A1 genotype modify the treatment effect. For example, if the doseresponse relationships suggested by the cubic spline models are true effects, we would expect patients with bilirubin levels Ͻ10 mol/L to derive greater benefit from niacin/statin combination treatment compared with those with higher levels. Drugs that stimulate heme oxygenase such as niacin will produce carbon monoxide and ferritin in equal measure to bilirubin, meaning that it will be difficult to conclude with certainty that bilirubin is the causal agent. Direct intravenous administration of bilirubin or its soluble precursor biliverdin has been shown to benefit rats exposed to endotoxins, 37 but use in humans requires further preclinical development. Other possible candidates for investigation are drugs that specifically inhibit or downregulate UGT1A1 activity, but strategies to increase bilirubin levels in this way should be balanced against a potential increased risk of gallstones 38 or adverse drug reactions. 39 To the best of our knowledge, this is the largest longitudinal analysis of the association between bilirubin level and CVD events and one of the first studies with sufficient statistical power to demonstrate that the relationships are similar for men and women. During 2010, 89% of new statin prescriptions recorded in THIN included a bilirubin measure in the 3 months before prescription, suggesting that our cohort is broadly representative of patients newly prescribed statins in primary care across the United Kingdom. The mean and standard deviation of serum bilirubin levels in this cohort were nearly identical to those of healthy British men and women reported by others. 40 We found no strong evidence that differences in drug efficacy (LDL reduction) or toxicity explained the relationship between pretreatment bilirubin and CVD events. There was a slightly greater LDL reduction among patients with higher bilirubin levels, which may reflect differences in glucuronidation capacity or other characteristics such as treatment adherence. Overall, it seems that the associations are mediated mainly by the protective properties of bilirubin and/or the influence of unmeasured environmental CVD risk factors that are also associated with lower bilirubin level.
The purported pleotropic effects of statins have led to speculation on a protective mechanism distinct from LDL reduction. Animal studies have reported that statin administration increases heme oxygenase expression in heart and lung tissue, together with an increase in serum bilirubin level. 41, 42 Increases in heme oxygenase levels in response to statins have also been identified in human endothelial tissues, 43 and studies in humans show a modest increase in serum bilirubin that is independent of changes in liver enzymes of Ϸ10% to 20% after statin treatment. 44, 45 If heme oxygenase stimulation explains some the mechanism of statin efficacy, via bilirubin or other byproducts, and this stimulation is more pronounced in patients with a higher bilirubin level measured before prescription, this could also partially explain the negative relationships with CVD described in the present study. However, if this were the case, we might expect our results to appear stronger relative to similar epidemiological studies in non-statin-treated cohorts, whereas they were in fact slightly weaker. In addition, Hu and Tomlinson 44 recently found that bilirubin increases after statin prescription were independent of UGT1A1 variants in Chinese patients with hypercholesterolemia. We could not account for over-the-counter prescriptions of low-dose statins, and it is possible that some of the cohort were not treatment naïve at the time of CVD risk assessment. If people with low bilirubin were more likely to be on over-the-counter statin treatment before baseline, the associations could have been diluted. Read codes have been shown to be accurate compared with other reliable sources, 20 but there is still the potential for misclassification bias. The associations with bilirubin appeared to be more pronounced for the harder outcomes (MI and death), which might reflect some misclassification of CVD and CHD with respect to bilirubin level. For example, a raised bilirubin level might prompt further general investigations by the clinician and could lead to a CVD diagnosis. In addition, patients with higher bilirubin levels may have higher levels of education, not fully accounted for by adjustment for social deprivation, and be more likely to be informed on the symptoms of CVD. It is also worth noting that the patients included in the THIN cohort were those already deemed at risk of CVD by the clinician and appropriate for statin prescription, and although others have reported that bilirubin can improve the performance of CVD risk scores applied to the general population, 46 we could not examine this in the present study.
Serum bilirubin is a cheap and routine test that captures risk information beyond that of conventional CVD risk factors recorded before statin prescription. Further research is warranted to examine whether the inclusion of bilirubin can improve the performance of existing CVD risk scores used in routine practice and to determine whether a causal relation-ship exists between serum bilirubin level and the development of CVD.
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